Skip to main content

Please note that this is a beta version of our website. Should you encounter any bugs, glitches, lack of functionality or other problems on the website, please let us know immediately so we can rectify these accordingly. Your help in this regard is greatly appreciated! You can email us.

Login to North West London Pathology – consumables service

If you need a new account or you have a query about your order, please telephone the pathology call centre on 0203 313 5353.

If you have forgotten your password you can reset this yourself. Please click here if you have forgotten your password.

Results Line and Enquiries

0203 313 5353

Cancer antigen 19-9 (CA 19-9)

Category Biochemistry >> Oncology
Test background

CA 19-9 is a tumour-associated glycoprotein mucin that bears a specific carbohydrate epitope, the sialylated Lewisa blood group antigen. The assay is based upon a monoclonal antibody, 1116-NS-19-9 which recognises this carbohydrate antigenic determinant. Approximately 7 % of the population who have the phenotype Lewisa negative are prevented by their genetic constitution from synthesising CA 19-9 antigen. Serum CA 19-9 concentrations are elevated in 70-92 % of patients with pancreatic carcinomas. This marker may also prove helpful in monitoring treatment response in other CA 19-9 positive carcinomas. CA 19-9 may be elevated in cancers, including hepatocellular, gastric, colorectal, lung and gall bladder cancers. A variety of conditions, including biliary obstruction, cholestasis, cholangitis, hepatic cirrhosis, cystic fibrosis, acute and chronic pancreatitis, may also cause elevation of CA 19-9.

Clinicial Indications

Pancreatic cancer

Diagnosis: since CA 19-9 may be elevated in benign conditions it is not recommended for screening purposes and diagnostic utility should be limited to case finding in symptomatic patients in conjunction with pancreatic imaging.

Prognosis and staging: baseline CA 19-9 can be used to guide treatment and follow-up and may have a prognostic value in absence of cholestasis. CA 19-9 carries independent predictive value for successful resection of pancreatic cancer and overall survival.

Treatment monitoring: CA 19-9 measurements are recommended in conjunction with imaging to monitor response to therapy.

Surveillance: studies have indicated that CA19-9 has high sensitivity for detection of relapse following pancreatectomy.

Reference range

<37 kIU/L

Sample & container required SST (gold top) preferred, serum (red top) accepted
Sample volume 0.5 mL
Turnaround time 4 days
Notes

Abbott Alinity